Results 51 to 60 of about 2,835,481 (302)

Bone and Soft Tissue Neoplasms in Infants Versus Older Children: A Report From the Cancer in Young People in Canada Program

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims Infant bone and soft tissue neoplasms present distinct clinical challenges and lack large‐scale data to inform treatment decisions. This study aims to characterize bone and soft tissue neoplasms in infants in Canada and to compare their outcomes with those of older pediatric patients.
Samuel Sassine   +21 more
wiley   +1 more source

Minimum Inhibitory Concentration (MIC) of rhodanine compounds Gram-negative pathogens.

open access: yes, 2016
Minimum Inhibitory Concentration (MIC) of rhodanine compounds Gram-negative pathogens.
Charles R. Ashby Jr (369799)   +4 more
core   +1 more source

Lorlatinib‐Containing Therapy for MYCN‐Amplified, ALK‐Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Central nervous system (CNS) relapse of neuroblastoma carries a poor prognosis, and craniospinal irradiation (CSI) poses substantial long‐term toxicity in young children. We report a toddler with MYCN‐amplified neuroblastoma harboring somatic ALK R1275Q who developed extensive leptomeningeal relapse with paraplegia.
Jinwoo Kim   +11 more
wiley   +1 more source

Structural elucidation, molecular docking, α-amylase and α-glucosidase inhibition studies of 5-amino-nicotinic acid derivatives

open access: yesBMC Chemistry, 2020
In this study, 5-amino-nicotinic acid derivatives (1–13) have been designed and synthesized to evaluate their inhibitory potential against α-amylase and α-glucosidase enzymes.
Muhammad Nawaz   +8 more
doaj   +1 more source

Minimum inhibitory concentration (MIC) of compounds against six fungal strains.

open access: yes, 2018
Minimum inhibitory concentration (MIC) of compounds against six fungal strains.
Mukesh Kumari (5122631)   +6 more
core   +1 more source

Recommended Phase 2 Dose for Abemaciclib in Combination With Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results From Study JPCS Part B

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclin‐dependent kinase 4/6 (CDK4/6) pathway aberrations, including CDK4 or CCND1 amplification, CDKN2A/B loss, retinoblastoma (RB) dysregulation, and cyclin D overexpression, are relevant for pediatric cancers. Abemaciclib, a selective CDK4/6 inhibitor with preferential CDK4 activity and central nervous system (CNS) penetration ...
Alvaro Lassaletta   +10 more
wiley   +1 more source

Three New Benzophenone Derivatives from Selaginella tamariscina

open access: yesMolecules, 2023
Six compounds including three new benzophenones, selagibenzophenones D-F (1–3), two known selaginellins (4–5) and one known flavonoid (6), were isolated from Selaginella tamariscina.
Jiayin Long   +8 more
doaj   +1 more source

Inhibitory effects of the selected title compounds against DNA gyrase.

open access: yes, 2013
Inhibitory effects of the selected title compounds against DNA gyrase.
Yong Yin (51909)   +5 more
core   +1 more source

The selected compounds and common drugs for SAR-CoV-2 3CLpro inhibitory activity assay.

open access: yes, 2022
The selected compounds and common drugs for SAR-CoV-2 3CLpro inhibitory activity assay.
Tuanjai Somboon (12981788)   +9 more
core   +1 more source

Effect of DFPP on Ferroptosis in Peripheral Blood CD14+ Monocytes of Hyperlipidemic Patients Involving the ACSL4/LPCAT3/ALOX5 Pathway

open access: yesTherapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid‐lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non‐drug treatment using double‐filtration plasmapheresis (DFPP) on CD14+
Yun Cheng   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy